CROs & CMOs incl. Pharma Packaging

Biomanufacturing, packaging & contract research – COVID-19 vaccine manufacturing has significantly impacted the supply chains of producers of mRNA gene therapies and vector-based vaccines and their CDMOs and CROs: While development and production of biologics for chronic indication must go on, delivery times for raw materials, bags, filters etc. are getting longer and longer.

In the light of a projected high need for gene and cell therapy as well as for booster vaccines protecting against viral variants, producers are ramping up their capacities, expand their strategic reach through M&A, and try to secure critical raw materials and qualified staff - the same is true for CROs, who face a post-pandemic boom due to delays in clinical testing caused by COVID-19 priorisation.  Furthermore, CROs and CDMOs try to automate production of autologous ATMP production, integrate AI into process development and data analytics to respond to the huge business opportunity.

New formats drive growth

Recruit the right people for the early phase work

Revolutionary approach for evolutionary research

Analytical demand on CRISPR therapies